The first study of its kind for the treatment of patients : the phase II study examines the safety and possible benefits of CERE-110. CERE-110 contains a gene and is injected during surgery into a part of the brain affected by Alzheimer's disease.
The gene will instruct brain cells to produce more of a protein, called Nerve Growth Factor or NGF, which helps nerve cells survive and function properly. The transfer of this gene into the brain is a medical technique called gene therapy. Though the goal is to to stop the progression of Alzheimer's disease, its a good move because still there are drugs to be innovated for the complete cure. Congrats Dr. Chris Kalhorn.
Ref : http://explore.georgetown.edu/news/?ID=44677&PageTemplateID=295
No comments:
Post a Comment